The China National Medical Products Administration (NMPA) has further approved Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in pediatric patients. 17 August 2021
US biotech Incyte and China’s InnoCare have announced that Incyte and a subsidiary of InnoCare have entered into a collaboration and license agreement for the development and commercialization of tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in Greater China. 17 August 2021
Japan’s largest drugmaker Takeda is currently developing multiple microbiome-targeting agents through a number of collaborations with innovative small companies. 17 August 2021
China’s Brii Biosciences has announced that the Phase III portion of the ACTIV-2 study evaluating its monoclonal neutralizing antibody combination therapy, BRII-196/BRII-198 has completed enrollment of 846 participants, in sites in the USA, Brazil, South Africa, Mexico and Argentina. 16 August 2021
Tokyo-based drugmaker Eisai has announced the Japanese launch of Tazverik Tablets 200mg (tazemetostat hydrobromide) for relapsed or refractory EZH2 gene mutation-positive follicular lymphoma, when standard treatment is not applicable. 16 August 2021
Physics-based US software specialist Schrödinger and China’s Zai Lab Limited have entered into a global discovery, development and commercialization collaboration focused on a novel program in oncology targeting DNA damage response. 16 August 2021
US biotech Seagen and Chinese biopharma RemeGen have announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody-drug conjugate (ADC). 10 August 2021
Japanese pharma major Eisai closed up 1.2% at 9,092 yen today, as it announced that its anti-epileptic drug (AED) Fycompa (perampanel) has obtained two additional approvals in China. 2 August 2021
Minovia Therapeutics and Japan’s Astellas Pharma on Friday announced a worldwide strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction. 2 August 2021
Japanese biotech PeptiDream has entered into a license and collaboration agreement with US RNAi therapeutics company Alnylam Pharmaceuticals to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver. 31 July 2021
Danish allergy immunotherapy specialist ALK Abello has announced an exclusive licensing agreement with China Grand Pharmaceutical and Healthcare Holdings (Grandpharma), that will see ALK’s adrenaline auto-injector (AAI) Jext registered and launched in China, and will expand ALK's presence in the country. 31 July 2021
Japanese drugmaker Takeda closed 2% down after Tokyo’s trading day on Friday, having presented its financial results from the first quarter, under Japan’s April to March financial year. 30 July 2021
The Japanese pairing of PeptiDream and Takeda have announced an expansion of their research collaboration and exclusive license agreement to create peptide-drug conjugates (PDCs) for several central nervous system (CNS) targets. 28 July 2021
Indian drugmaker Intas Pharmaceuticals has been granted rights to commercialize DMB-3115, a proposed biosimilar to Janssen’s Stelara (ustekinumab), in all global markets excluding Japan, South Korea and certain other Asian countries. 26 July 2021
Japan’s Chugai Pharmaceutical today said it will construct a new manufacturing building for active pharmaceutical ingredients (APIs) of small and mid-size molecule drugs in the Fujieda Plant. 26 July 2021
The Australian government in the state of Victoria has announced that a novel coronavirus vaccine candidate will enter clinical testing in October, with preliminary results expected in the first half of 2022. 23 July 2021
Swiss pharma giant Roche today announced that Japan’s Ministry of Health Labor and Welfare (MHLW) has approved Ronapreve (casirivimab and imdevimab), for the indication of SARS-CoV-2 infection in patients with mild to moderate COVID-19 via intravenous infusion. 20 July 2021
The Israeli Ministry of Health (IL MOH) has approved Tevimbra (tislelizumab) as monotherapy for the treatment of adult patients with unresectable or metastatic oesophageal squamous cell carcinoma (OESCC). 20 September 2024
Daiichi Sankyo’s today revealed that its Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine National Health Service (NHS) commissioning in England and Wales. 19 September 2024
Gene therapy research in Japan has gained significant momentum due to the SAKIGAKE designation system and government-led initiatives like the “Project for Regenerative/Cellular Medicine and Gene Therapies” to accelerate research and development (R&D) to create new technologies for gene/cell therapy. 18 September 2024
The HERTHENA-Lung02 Phase III trial of patritumab deruxtecan, in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase inhibitor (TKI) treatment, has met its primary endpoint. 17 September 2024
US biotech Capricor Therapeutics has entered into a binding term sheet with Japanese drugmaker Nippon Shinyaku for the commercialization and distribution in Europe of Capricor’s lead asset, deramiocel. 17 September 2024
Women’s health focussed company Organon China today revealed that it has entered into license and supply agreements with Shanghai Bao Pharmaceutical, acquiring the exclusive commercialization rights to its investigational asset, SJ02, in China Mainland. 13 September 2024
On Thursday, the US Food and Drug Administration released a Drug Safety Communication warning that Veozah (fezolinetant), which is used to treat hot flashes due to menopause, can cause rare but serious liver injury. 13 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
Detailed results were released from the TROPION-Lung01 Phase III trial, which showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato-DXd) compared to docetaxe. 10 September 2024
Chinese companies Innovent Biologics and GenFleet have recently secured approval from China’s National Medical Products Administration (NMPA) for Dupert (fulzerasib). 9 September 2024
Summit Therapeutics on Sunday announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab compared to Merck & Co’s) mega blockbuster drug Keytruda (pembrolizumab). 9 September 2024
Organon KK, a Japan subsidiary of Organon & Co, announced that the primary endpoint was achieved in a domestic Phase III clinical trial evaluating the efficacy and safety of OG-8276A 6 September 2024
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Privately-held Chinese biotech EpimAb Biotherapeutics and Vignette Bio have entered into a license agreement for EpimAb’s BCMA-targeting T-cell engager (TCE) EMB-06. 5 September 2024
Rigel Pharmaceutical’s shares dipped 4.4% to $12 .85 by late morning, despite announcing what could be a lucrative deal for the company. 3 September 2024
Chinese gene therapy specialist YolTech Therapeutics has entered into an exclusive licensing agreement with Salubris Pharmaceuticals (SHE: 002294). 3 September 2024
Japan’s Nxera Pharma today announced that it will receive a $35 million payment from Neurocrine Biosciences, triggered by the successful completion of the Phase II trial with NBI-1117568 (NBI-‘568) in adults with schizophrenia. 2 September 2024
Chinese biopharma Hutchmed on Friday announced that it has voluntarily withdrawn its supplemental New Drug Application (NDA) in China for fruquintinib. 2 September 2024
Jacobio Pharma announced that it has granted the China rights to KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 to Shanghai Allist Pharmaceuticals. 2 September 2024